Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Autor: Röllig C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Steffen B; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany., Mikesch JH; Department of Medicine A, University Hospital Münster, Münster, Germany., Alakel N; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Herbst R; Department of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany., Hänel M; Department of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany., Noppeney R; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Hanoun M; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Kaufmann M; Department of Hematology, Robert-Bosch-Krankenhaus, Stuttgart, Germany., Weinbergerova B; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Schäfer-Eckart K; Department of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Germany., Sauer T; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Neubauer A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany., Burchert A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany., Baldus CD; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Mertová J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Jost E; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital Aachen & CIO ABCD Aachen, RWTH Aachen, Aachen, Germany., Niemann D; Department of Hematology, Oncology and Palliative Care, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany., Novák J; Department of Haematology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Hràdec Kralovè, Czech Republic., Krause SW; Department of Internal Medicine V, Universitätsklinikum Erlangen, Erlangen, Germany., Scholl S; Klinik für Innere Medizin, Universitätsklinikum Jena, Jena, Germany., Hochhaus A; Klinik für Innere Medizin, Universitätsklinikum Jena, Jena, Germany., Held G; Klinik für Innere Medizin 1, Westpfalzklinikum, Kaiserslautern, Germany., Szotkowski T; Department of Hemato-Oncology, Palacký University, Olomouc, Czech Republic., Rank A; II. Medizinische Klinik, Universitätsklinikum Augsburg, Augsburg, Germany., Schmid C; II. Medizinische Klinik, Universitätsklinikum Augsburg, Augsburg, Germany., Fransecky L; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Kayser S; Department of Internal Medicine I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.; NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Insitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Schaich M; Department of Hematology, Oncology and Palliative Care, Rems-Murr-Kliniken, Winnenden, Germany., Kramer M; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Fiebig F; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Haake A; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Schetelig J; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Middeke JM; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Stölzel F; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Platzbecker U; Department of Internal Medicine I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany., Thiede C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.; Agendix GmbH, Dresden, Germany., Müller-Tidow C; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Berdel WE; Department of Medicine A, University Hospital Münster, Münster, Germany., Ehninger G; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Serve H; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Bornhäuser M; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Jan; Vol. 43 (1), pp. 65-74. Date of Electronic Publication: 2024 Sep 16.

Sharp-force injuries: Postmortem CT angiography.

Autor: Handlos P, Uvíra M, Vojtek V, Smutná M, Mertová J

Publikováno v: Soudni lekarstvi [Soud Lek] 2024; Vol. 69 (3), pp. 34-36.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.